Novo Nordisk is going all in on Ozempic, its once-weekly GLP-1 injection for diabetes that was approved by the FDA in December 2017. The Danish pharma has shifted marketing spend away from Victoza, its once-daily GLP-1, to promote the new drug as it makes a push on TV...